Literature DB >> 32196586

Circular RNA-ABCB10 suppresses hepatocellular carcinoma progression through upregulating NRP1/ABL2 via sponging miR-340-5p/miR-452-5p.

W Yang1, H-Y Ju, X-F Tian.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the most common liver malignancies worldwide with a high rate of recurrence and mortality. Circular RNA-ABCB10 (circ-ABCB10), 724 nucleotides in length, plays a pro-oncogenic role in tumor progression. However, the role of circ-ABCB10 in HCC is still unknown. Therefore, the objective of this study was to determine the role of circ-ABCB10 in HCC progression in vitro and in vivo and to elucidate the underlying mechanism. PATIENTS AND METHODS: Tumor tissues from patients with HCC and multiple HCC cell lines were used for in vitro experiments and a mouse xenograft model was used for in vivo experiments. Quantitative Real Time-PCR, Western blots, lentivirus transfection, cell proliferation assays, cloning formation, migration, and invasion assays, flow cytometry, Luciferase reporter assays, and biotin-coupled probe pull-down assays were performed to investigate the mechanism underlying the effect of circ-ABCB10 on HCC.
RESULTS: The results revealed that the expression of circ-ABCB10 was downregulated in both HCC tissues and cell lines and was positively correlated with histological grade and tumor size. The overexpression of circ-ABCB10 exerted inhibitory effects on HCC cell proliferation, invasion, and migration. Mechanistic and functional evidence together showed that circ-ABCB10 elevated expressions of neuropilin-1 (NRP1) and ABL related gene (ABL2) by sponging miR-340-5p and miR-452-5p, which inhibited the progression of HCC. Furthermore, the in vivo study suggests that circ-ABCB10 inhibited tumor growth in nude mice.
CONCLUSIONS: In brief, the results demonstrate that circ-ABCB10 exerts anti-tumor roles via miR-340-5p/miR-452-5p-NRP1/ABL2 signaling axis, providing a promising biomarker and therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32196586     DOI: 10.26355/eurrev_202003_20501

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  The Emerging Roles of Circ-ABCB10 in Cancer.

Authors:  Zhenjun Huang; Renfeng Shan; Wu Wen; Jianfeng Li; Xiaohong Zeng; Renhua Wan
Journal:  Front Cell Dev Biol       Date:  2022-05-13

2.  Circ_LDLR Knockdown Suppresses Progression of Hepatocellular Carcinoma via Modulating miR-7/RNF38 Axis.

Authors:  Yuming Jia; Shengchao Li; Meng Zhang; Zhilei Zhang; Chao Wang; Chong Zhang; Wuhan Yang; Li Peng; Zhuo Xu
Journal:  Cancer Manag Res       Date:  2021-01-13       Impact factor: 3.989

3.  Circular RNA 0001313 Knockdown Suppresses Non-Small Cell Lung Cancer Cell Proliferation and Invasion via the microRNA-452/HMGB3/ERK/MAPK Axis.

Authors:  Shihao Zhang; Jiansheng Liu; Taiwen Yuan; Huiyu Liu; Chengwei Wan; Yonghong Le
Journal:  Int J Gen Med       Date:  2020-12-10

4.  Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR‑153‑3p.

Authors:  Ge Yang; Xianyong Li; Jingbo Liu; Shengjie Huang; Yaguang Weng; Jing Zhu; Daiqiong Lin; Ou Jiang
Journal:  Oncol Rep       Date:  2021-01-19       Impact factor: 3.906

Review 5.  Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma.

Authors:  Rui Liao; Lei Liu; Jian Zhou; Xufu Wei; Ping Huang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

Review 6.  Circular RNAs in gastrointestinal cancer: Current knowledge, biomarkers and targeted therapy (Review).

Authors:  Xiaorui Zhao; Yue Wang; Qiongfang Yu; Pei Yu; Qiaoyu Zheng; Xue Yang; Dian Gao
Journal:  Int J Mol Med       Date:  2020-09-16       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.